Vertex Pharmaceuticals is acquiring Crinetics Pharmaceuticals for $10 billion, marking the Boston biopharma company’s entry into what Stifel analysts call an “emerging specialty endo space.”
Crinetics, an endocrine specialist, will offer Vertex an FDA-approved acromegaly pill called Palsonify and a treatment for late-stage congenital adrenal hyperplasia (CAH).
Stifel analysts opened their note Monday evening with “Wow!” and said that specialty endocrinology markets “represent emerging white space blockbuster opportunities.”
Announced as part of the terms of the contract Monday eveningVertex will pay $85 per Crinetics share, for a total value of about $10 billion. That purchase price represents a premium of about 102% for Crinetics, which ended Monday’s trading session at $42.03 per share, according to Stifel.
The companies expect to close the transaction in the third quarter.
Palsonify is a daily medication approved in September 2025 for acromegaly. Patients with the rare hormonal disorder suffer from abnormal bone and organ growth, leading to complications such as cardiomyopathy and pain. Palsonify generated until the end of 2025 $5.4 million in sales, is growing $10.3 million in the first quarter of this year.
Also joining Vertex is atumelnant, another daily oral therapy, this time for CAH, a genetic disorder of the adrenal gland that can disrupt growth and development. The adrenocorticotropic hormone receptor antagonist is currently in late stages of development.
Together, Vertex expects Palsonify – which it says has “blockbuster potential” – and atumelnant to potentially have combined annual revenue of over $5 billion at their peak. Stifel is similarly optimistic about these assets and the overall value Crinetics will bring to Vertex. “As long as Atumelnant does not encounter a significant security issue,” the company said, “the deal will open up another interesting avenue of growth for VRTX over time.”
The purchase of Crinetics is the largest deal in Vertex’s history, BMO Capital Markets said in a statement on Monday, and is one of the most valuable acquisitions this year, just behind that of GSK $10.6 billion game for Nuvalent Bio last month and Sun Pharma’s Acquisition valued at $11.75 billion from Organon in April.
While Stifel viewed the acquisition of Crinetics as an investment in endocrinology, BMO sees the deal as Vertex strengthening its leadership position in rare diseases.
“We view the deal positively for Vertex as the company works to expand its rare disease offerings and leverage its experience in commercializing specialty products,” BMO noted, pointing to the company’s cystic fibrosis portfolio, which remains its strongest revenue driver. Vertex reported in the first quarter $1.78 billion in cystic fibrosis sales7% more than last year.
Vertex also looks forward to potential approval for its fusion protein povetacicept in the treatment of IgA nephropathy later this year. If approved, the drug could be a “new pillar of its business,” BMO wrote in a May 9 statement.
While some analysts may view Vertex Pharmaceuticals’ first-quarter results as “unremarkable,” BMO Capital Markets wrote on Monday, the second half of 2026 could be big for the biotech with the potential approval of IgAN therapy povetacicept.
May 5, 2026
·
2 minutes read
·
https://www.biospace.com/deals/vertex-inks-10b-crinetics-buy-entering-white-space-blockbuster-opportunity
